UF-led researchers link new genetic mutation to increased risk of Parkinson’s
New research by a University of Florida-led international team has revealed evidence linking a new genetic mutation to greater risk of developing Parkinson’s disease.
New research by a University of Florida-led international team has revealed evidence linking a new genetic mutation to greater risk of developing Parkinson’s disease.
University of Florida neurogeneticist Matthew Farrer contributed to the new Michael J. Fox Foundation Global Genetic PD Cohort.
In a recent study, researchers at the Norman Fixel Institute for Neurological Diseases at UF Health and the University of Florida College of Pharmacy used Medicare data to compare the rate of hospitalizations and deaths between two common Parkinson’s disease medications: pimavanserin and quetiapine.
UF neuroscientists provide preclinical evidence for adoptive cellular therapy as a potential immunotherapy treatment to improve symptoms in genetic form of Parkinson’s.
A recent Parkinson’s Foundation study estimates that nearly 90,000 people in the U.S. are diagnosed with Parkinson’s disease each year.
According to a pilot study at the Norman Fixel Institute for Neurological Diseases, group physical and occupational therapy sessions may be beneficial for symptom improvement and motivation levels in people living with Parkinson’s.
Study co-authored by Dr. Karen Hegland found sensorimotor training for airway protection improved cough-related outcomes in Parkinson’s patients.
Researchers at the University of Florida study the impact dopamine replacement medications like Levodopa have on the facial expressions of a person living with Parkinson’s disease.
Amid questions about the late boxing great’s symptoms, UF’s Dr. Michael Okun and colleagues conclude his primary diagnosis was young-onset Parkinson’s disease.
Drs. Irene Malaty and Bhavana Patel co-author review in Practical Neurology about new agents, formulations and procedures to improve Parkinson’s treatment.